Ying T. Shi B. Kelly P.J. et al.

Death after Kidney Transplantation: An Analysis by Era and Time Post-Transplant.

J Am Soc Nephrol. 31: 2887-2899

Post-transplant diabetes mellitus in patients with solid organ transplants.

Nat Rev Endocrinol. 15: 172-188Schrezenmeier E. Lehner L.J. Merkel M. et al.

What happens after graft loss? A large, long-term, single-center observation.

Transpl Int. Terasaki P.I. Vredevoe D.L. Porter K.A. et al.

Serotyping for homotransplantation. V. Evaluation of a matching scheme.

Transplantation. 4: 688-699Shi X. Liu R. Xie X. et al.

Effect of human leukocyte antigen mismatching on the outcomes of pediatric kidney transplantation: a systematic review and meta-analysis.

Nephrol Dial Transplant. 32: 1939-1948Mumford L. Maxwell H. Ahmad N. et al.

The impact of changing practice on improved outcomes of paediatric renal transplantation in the United Kingdom: a 25 years review.

Transpl Int. 32: 751-761Ruck J.M. Jackson A.M. Massie A.B. et al.

Temporal Changes in the Impact of HLA Mismatching Among Pediatric Kidney Transplant Recipients.

Transplantation. 103: 1267-1271Takemoto S. Terasaki P.I. Cecka J.M. et al.

Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. The UNOS Scientific Renal Transplant Registry.

N Engl J Med. 327: 834-839Williams R.C. Opelz G. McGarvey C.J. et al.

The Risk of Transplant Failure With HLA Mismatch in First Adult Kidney Allografts From Deceased Donors.

Transplantation. 100: 1094-1102

Current role of human leukocyte antigen matching in kidney transplantation.

Curr Opin Organ Transplant. 18: 438-444

Association of HLA mismatch with death with a functioning graft after kidney transplantation: a collaborative transplant study report.

Am J Transplant. 12: 3031-3038

Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades.

Transplantation. 84: 137-143

https://www.eurotransplant.org/wp-content/uploads/2020/01/H4-Kidney-2021.1-March-2021.pdf.

https://www.health.govt.nz/system/files/documents/pages/nrts-nz-kidney-allocation-scheme-march2020.pdf.

Roberts J.P. Wolfe R.A. Bragg-Gresham J.L. et al.

Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups.

N Engl J Med. 350: 545-551Friedewald J.J. Samana C.J. Kasiske B.L. et al.

The kidney allocation system.

Surg Clin North Am. 93: 1395-1406

http://antiphishing.aphp.fr/2/ZGVuaXMuZ2xvdHpAYXBocC5mcnxWUkMxMzcwMzI5 /www.agence-biomedecine.fr/IMG/pdf/v25guide-regles-de-repartition.pdf

https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/22127/pol186.pdf.

https://www.transplantmanitoba.ca/transplant-program/kidney-allocation.

Humoral theory of transplantation.

Am J Transplant. 3: 665-673

A personal perspective: 100-year history of the humoral theory of transplantation.

Transplantation. 93: 751-756Nankivell B.J. Borrows R.J. Fung C.L. et al.

The natural history of chronic allograft nephropathy.

N Engl J Med. 349: 2326-2333Delmonico F.L. Milford E.L. Goguen J. et al.

A novel united network for organ sharing region kidney allocation plan improves transplant access for minority candidates.

Transplantation. 68: 1875-1879Wiebe C. Gibson I.W. Blydt-Hansen T.D. et al.

Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.

Am J Transplant. 12: 1157-1167Wiebe C. Gibson I.W. Blydt-Hansen T.D. et al.

Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.

Am J Transplant. 15: 2921-2930Mehra N.K. Siddiqui J. Baranwal A. et al.

Clinical relevance of antibody development in renal transplantation.

Ann N Y Acad Sci. 1283: 30-42Loupy A. Hill G.S. Jordan S.C.

The impact of donor-specific anti-HLA antibodies on late kidney allograft failure.

Nat Rev Nephrol. 8: 348-357Aubert O. Loupy A. Hidalgo L. et al.

Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients.

J Am Soc Nephrol. 28: 1912-1923Lionaki S. Panagiotellis K. Iniotaki A. Boletis J.N.

Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation.

Clin Dev Immunol. 2013: 849835Schrezenmeier E. Lehner L.J. Merkel M. et al.

What happens after graft loss? A large, long-term, single-center observation.

Transpl Int. 34: 732-742Muduma G. Odeyemi I. Smith-Palmer J. Pollock R.F.

Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients.

Adv Ther. 33: 345-356

Impact of HLA matching and HLA antibodies in organ transplantation: a collaborative transplant study view.

Methods Mol Biol. 882: 267-277Tonelli M. Wiebe N. Knoll G. et al.

Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes.

Am J Transplant. 11: 2093-2109Bonani M. Achermann R. Seeger H. et al.

Dialysis after graft loss: a Swiss experience.

Nephrol Dial Transplant. 35: 2182-2190Brar A. Markell M. Stefanov D.G. et al.

Mortality after Renal Allograft Failure and Return to Dialysis.

Am J Nephrol. 45: 180-186Kosmoliaptsis V. Gjorgjimajkoska O. Sharples L.D. et al.

Impact of donor mismatches at individual HLA-A, -B, -C, -DR, and -DQ loci on the development of HLA-specific antibodies in patients listed for repeat renal transplantation.

Kidney Int. 86: 1039-1048Foster B.J. Dahhou M. Zhang X. et al.

Impact of HLA mismatch at first kidney transplant on lifetime with graft function in young recipients.

Am J Transplant. 14: 876-885Iniotaki-Theodoraki A.G. Boletis J.N. Trigas G. et al.

Humoral immune reactivity against human leukocyte antigen (HLA)-DQ graft molecules in the early posttransplantation period.

Transplantation. 75: 1601-1603Ozawa M. Rebellato L.M. Terasaki P.I. et al.

Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience.

Clin Transpl. : 265-290DeVos J.M. Gaber A.O. Knight R.J. et al.

Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation.

Kidney Int. 82: 598-604Willicombe M. Brookes P. Sergeant R. et al.

De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy.

Transplantation. 94: 172-177Everly M.J. Rebellato L.M. Haisch C.E. et al.

Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.

Transplantation. 95: 410-417Freitas M.C. Rebellato L.M. Ozawa M. et al.

The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.

Transplantation. 95: 1113-1119Ticehurst E.H. Molina M.R. Frank R. et al.

Antibody-mediated rejection in heart transplant patients: long-term follow up of patients with high levels of donor-directed anti-DQ antibodies.

Clin Transpl. : 409-414Irving C.A. Carter V. Gennery A.R. et al.

Effect of persistent versus transient donor-specific HLA antibodies on graft outcomes in pediatric cardiac transplantation.

J Heart Lung Transplant. 34: 1310-1317Lobo L.J. Aris R.M. Schmitz J. Neuringer I.P.

Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation.

J Heart Lung Transplant. 32: 70-77Kaneku H. O'Leary J.G. Banuelos N. et al.

De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients.

Am J Transplant. 13: 1541-1548Wozniak L.J. Hickey M.J. Venick R.S. et al.

Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation.

Transplantation. 99: 1416-1422

Clinical relevance of human leukocyte antigen antibodies in liver, heart, lung and intestine transplantation.

Curr Opin Organ Transplant. 18: 463-469Senev A. Coemans M. Lerut E. et al.

Eplet Mismatch Load and De Novo Occurrence of Donor-Specific Anti-HLA Antibodies, Rejection, and Graft Failure after Kidney Transplantation: An Observational Cohort Study.

J Am Soc Nephrol. 31: 2193-2204Wiebe C. Kosmoliaptsis V. Pochinco D. et al.

HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity.

Am J Transplant. 19: 1708-1719Wiebe C. Pochinco D. Blydt-Hansen T.D. et al.

Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes.

Am J Transplant. 13: 3114-3122Davis S. Wiebe C. Campbell K. et al.

Adequate tacrolimus exposure modulates the impact of HLA class II molecular mismatch: a validation study in an American cohort.

Am J Transplant. 21: 322-328Lim W.H. Chapman J.R. Coates P.T. et al.

HLA-DQ Mismatches and Rejection in Kidney Transplant Recipients.

Clin J Am Soc Nephrol. 11: 875-883Leeaphorn N. Pena J.R.A. Thamcharoen N. et al.

HLA-DQ Mismatching and Kidney Transplant Outcomes.

Clin J Am Soc Nephrol. 13: 763-771Walsh R.C. Brailey P. Girnita A. et al.

Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition.

Transplantation. 91: 1218-1226Senev A. Lerut E. Van Sandt V. et al.

Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation.

Am J Transplant. 19: 3100-3113Wiebe C. Rush D.N. Nevins T.E. et al.

Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development.

J Am Soc Nephrol. 28: 3353-3362Snanoudj R. Kamar N. Cassuto E. et al.

Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppression.

Kidney Int. 95: 1471-1485Coca A. Arias-Cabrales C. Valencia A.L. et al.

Validation of a survival benefit estimator tool in a cohort of European kidney transplant recipients.

Sci Rep. 10: 17109Li B. Cairns J.A. Johnson R.J. et al.

Equity-Efficiency Trade-offs Associated With Alternative Approaches to Deceased Donor Kidney Allocation: A Patient-level Simulation.

Transplantation. 104: 795-803Clayton P.A. McDonald S.P. Snyder J.J. et al.

External validation of the estimated posttransplant survival score for allocation of deceased donor kidneys in the United States.

Am J Transplant. 14: 1922-1926Mosbruger T.I. Dinou A. Duke I.L. et al.

Utilizing nanopore sequencing technology for the rapid and comprehensive characterization of eleven HLA loci; addressing the need for decesed donor experdited HLA typing.

Hum Immunol. 81: 413-422Tambur A.R. Rosati J. Roitberg S. et al.

Epitope analysis of HLA-DQ antigens: what does the antibody see?.

Transplantation. 98: 157-166Tambur A.R. Audry B. Antoine C. et al.

Harnessing Scientific and Technological Advances to Improve Equity in Kidney Allocation Policies.

Am J Transplant. 17: 3149-3158Engen R.M. Jedraszko A.M. Conciatori M.A. Tambur A.R.

Substituting imputation of HLA antigens for high-resolution HLA typing: Evaluation of a multiethnic population and implications for clinical decision making in transplantation.

Am J Transplant. 21: 344-352Manski C.F. Tambur A.R. Gmeiner M.

Predicting kidney transplant outcomes with partial knowledge of HLA mismatch.

Proc Natl Acad Sci U S A. 116: 20339-20345Senev A. Emonds M.P. Van Sandt V. et al.

The clinical importance of extended 2nd field high-resolution HLA genotyping for kidney transplantation.

Am J Transplant. Gokmen M.R. Lombardi G. Lechler R.I.

The importance of the indirect pathway of allorecognition in clinical transplantation.

Curr Opin Immunol. 20: 568-574Chong A.S. Rothstein D.M. Safa K. Riella L.V.

Outstanding questions in transplantation: B cells, alloantibodies, and humoral rejection.

Am J Transplant. 19: 2155-2163

Indications, risks and impact of failed allograft nephrectomy.

Transplant Rev (Orlando). 33: 48-54Harding K. Mersha T.B. Pham P.T. et al.

Health Disparities in Kidney Transplantation for African Americans.

Am J Nephrol. 46: 165-175Gebel H.M. Kasiske B.L. Gustafson S.K. et al.

Allocating Deceased Donor Kidneys to Candidates with High Panel-Reactive Antibodies.

Clin J Am Soc Nephrol. 11: 505-511Massie A.B. Luo X. Lonze B.E. et al.

Early Changes in Kidney Distribution under the New Allocation System.

J Am Soc Nephrol. 27: 2495-2501Bayat S. Macher M.A. Couchoud C. et al.

Individual and regional factors of access to the renal transplant waiting list in france in a cohort of dialyzed patients.

Am J Transplant. 15: 1050-1060Copley H.C. Elango M. Kosmoliaptsis V.

Assessment of human leukocyte antigen immunogenicity: current methods, challenges and opportunities.

Curr Opin Organ Transplant. 23: 477-485

Beyond ABO and human histocompatibility antigen: other histocompatibility antigens with a role in transplantation.

Curr Opin Organ Transplant. 13: 425-429Tambur A.R. Campbell P. Chong A.S. et al.

Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report.

Am J Transplant. 20: 2652-2668Tambur A.R. McDowell H. Hod-Dvorai R. et al.

The quest to decipher HLA immunogenicity: Telling friend from foe.

Am J Transplant. 19: 2910-2925Mallon D.H. Kling C. Robb M. et al.

Predicting Humoral Alloimmunity from Differences in Donor and Recipient HLA Surface Electrostatic Potential.

J Immunol. 201: 3780-3792Reynisson B. Alvarez B. Paul S. et al.

NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data.

Nucleic Acids Res. 48 ()Lachmann N. Niemann M. Reinke P. et al.

Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation.

Am J Transplant. 17: 3076-3086